Free Trial

Exelixis (EXEL) Stock Forecast & Price Target

$22.56
+0.05 (+0.22%)
(As of 07/18/2024 ET)

Exelixis - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 17 Wall Street analysts who have issued ratings for Exelixis in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 17 analysts, 7 have given a hold rating, and 10 have given a buy rating for EXEL.

Consensus Price Target

$26.13
15.80% Upside
High Forecast$32.00
Average Forecast$26.13
Low Forecast$18.00

According to the 17 analysts' twelve-month price targets for Exelixis, the average price target is $26.13. The highest price target for EXEL is $32.00, while the lowest price target for EXEL is $18.00. The average price target represents a forecasted upside of 15.80% from the current price of $22.56.

TypeCurrent Forecast
7/20/23 to 7/19/24
1 Month Ago
6/20/23 to 6/19/24
3 Months Ago
4/21/23 to 4/20/24
1 Year Ago
7/20/22 to 7/20/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
10 Buy rating(s)
9 Buy rating(s)
6 Buy rating(s)
Hold
7 Hold rating(s)
7 Hold rating(s)
6 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$26.13$26.13$26.29$25.09
Forecasted Upside15.80% Upside20.37% Upside20.61% Upside43.37% Upside
Get Exelixis Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.

EXEL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

EXEL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Exelixis Stock vs. The Competition

TypeExelixisMedical CompaniesS&P 500
Consensus Rating Score
2.59
2.71
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside15.80% Upside1,353.19% Upside9.09% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/14/2024Stephens
4 of 5 stars
S. Loganathan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageStrong-Buy ➝ Equal Weight$23.00+9.37%
5/3/2024HC Wainwright
3 of 5 stars
 Reiterated RatingBuy ➝ Buy$28.00+27.85%
5/1/2024TD Cowen
4 of 5 stars
 Boost TargetBuy ➝ Buy$25.00 ➝ $27.00+27.96%
5/1/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
4/11/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight$25.00+5.57%
4/10/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Outperform ➝ Market Outperform$27.00+14.55%
2/7/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$26.00 ➝ $28.00+35.46%
2/2/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$23.00 ➝ $25.00+16.44%
12/19/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$27.00+15.68%
12/15/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$31.00+32.99%
11/2/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$22.00 ➝ $23.00+14.26%
10/12/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$25.00 ➝ $27.00+25.58%
10/11/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$30.00+39.28%
9/13/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$32.00+45.12%
8/22/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$25.00 ➝ $29.00+35.70%
8/8/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Liu
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
8/8/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$18.00-11.11%
8/8/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$18.00-11.11%
3/9/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$23.00+40.59%
3/3/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$24.00+43.97%
2/8/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight$32.00+81.82%
1/26/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$29.00+67.34%
1/9/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$21.00 ➝ $20.00+15.81%
11/2/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$26.00 ➝ $21.00+23.60%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 07:59 AM ET.

EXEL Forecast - Frequently Asked Questions

What is Exelixis' forecast for 2024?

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for Exelixis is $26.13, with a high forecast of $32.00 and a low forecast of $18.00.

Should I buy or sell Exelixis stock right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last twelve months. There are currently 7 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" EXEL shares.

Does Exelixis's stock price have much upside?

According to analysts, Exelixis's stock has a predicted upside of 20.37% based on their 12-month stock forecasts.

What analysts cover Exelixis?

Exelixis has been rated by research analysts at HC Wainwright, Stephens, TD Cowen, and William Blair in the past 90 days.

Do Wall Street analysts like Exelixis more than its competitors?

Analysts like Exelixis less than other "medical" companies. The consensus rating score for Exelixis is 2.59 while the average consensus rating score for "medical" companies is 2.72. Learn more on how EXEL compares to other companies.


This page (NASDAQ:EXEL) was last updated on 7/19/2024 by MarketBeat.com Staff

From Our Partners